Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Idera Pharmaceuticals, Inc. (IDRA : NSDQ)
 
 • Company Description   
Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.

Number of Employees: 13

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.52 Daily Weekly Monthly
20 Day Moving Average: 2,692,248 shares
Shares Outstanding: 52.97 (millions)
Market Capitalization: $27.55 (millions)
Beta: 1.55
52 Week High: $1.71
52 Week Low: $0.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 12.94% 23.67%
12 Week 17.62% 32.19%
Year To Date -8.75% 11.47%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
505 EAGLEVIEW BLVD. SUITE 212
-
EXTON,PA 19341
USA
ph: 484-348-1600
fax: 617-679-5592
ir@iderapharma.com http://www.iderapharma.com
 
 • General Corporate Information   
Officers
Vincent J. Milano - Chief Executive Officer; President and Director
Michael Dougherty - Chairman of the Board of Directors
John J. Kirby - Chief Financial Officer
James A. Geraghty - Director
Mark Goldberg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45168K405
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 52.97
Most Recent Split Date: 7.00 (0.13:1)
Beta: 1.55
Market Capitalization: $27.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.07
Price/Cash Flow: 0.28
Price / Sales: -
EPS Growth
vs. Year Ago Period: 42.86%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -68.86
12/31/21 - 275.72
09/30/21 - 1,727.83
ROA
03/31/22 - -58.40
12/31/21 - 236.02
09/30/21 - 217.16
Current Ratio
03/31/22 - 7.74
12/31/21 - 7.00
09/30/21 - 6.88
Quick Ratio
03/31/22 - 7.73
12/31/21 - 7.00
09/30/21 - 6.88
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.49
12/31/21 - 0.56
09/30/21 - 0.63
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©